Health Management Associates
Federal Drug Pricing Overhaul Could Reshape Medicaid Pharmacy Spending
HMA reviews new executive branch efforts to lower drug costs through "most favored nation" pricing benchmarks, including confidential manufacturer agreements and new CMS Innovation Center models. The analysis notes that these MFN agreements are expected to give state Medicaid programs access to discounted pricing and require new drugs to launch domestically at internationally aligned prices, which has direct implications for Medicaid pharmacy budgets and state drug procurement strategies.
This is outside commentary from Health Management Associates, not part of Medicaid Monitor's independently scored news coverage.